Navigation Links
GEN reports on strategies to overcome blood-brain barrier
Date:2/5/2009

New Rochelle, NY, February 5, 2009The blood-brain barrier (BBB) remains a major obstacle to the successful delivery of drugs to treat central nervous system (CNS) disorders, reports Genetic Engineering and Biotechnology News (GEN). Researchers are exploring a variety of approaches to preserve the ability of the BBB to block harmful and toxic substances from entering the brain and to permit the passage of effective medicines for the treatment of CNS diseases, according to the February 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2778).

"The blood-brain barrier issue probably serves as the most significant roadblock to the treatment of central nervous system diseases," says John Sterling, Editor in Chief of GEN. "The key challenge is to treat people suffering from CNS disorders while trying to stay true to the physician's oath, 'First do no harm'."

One technology for enabling active transport of small molecule drugs across the BBB involves targeting endogenous nutrient transporters. These transporters are members of the solute carrier (SLC) transporter superfamily. Transport of small molecules across the BBB by these membrane proteins is known as carrier-mediated transport (CMT).

In order to design drugs that utilize CMT to cross the BBB, researchers modify their chemical structures so that they resemble nutrients that are transported across the BBB by specific SLCs. The prototypical drug that uses this strategy (which was developed long before mechanisms of CMT were known) is L-DOPA, the major current drug for Parkinson's disease. L-DOPA is used to replace dopamine that is lost due to degeneration of dopaminergic neurons in the substantia nigra of the brain.

Another major system that is used in normal mammalian physiology to enable needed molecules to cross the BBB is receptor-mediated transport (RMT). The brain uses RMT to transport proteins, peptides, and lipoproteins that are needed for brain function across the BBB. Examples of biomolecules that are transported into the brain via RMT include insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein (LDL).

In RMT, molecules in the circulation may bind to specific receptors on the luminal surface of brain capillaries (i.e., the surface that interfaces with the bloodstream). Upon binding, the receptor-ligand complex is internalized into the endothelial cell by a process called receptor-mediated endocytosis. The ligand may then be transported across the abluminal membrane of the endothelial cell (i.e., the membrane that interfaces with brain tissue) into the brain. This whole process is called receptor-mediated transcytosis.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. GEN reports on growing reliance on microfluidics technology
2. Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
3. GEN reports growing focus on PI3-kinase pathway in cancer research
4. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
5. Orchid Cellmark Reports Third Quarter 2008 Financial Results
6. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
7. Synaptics Reports Record Results for First Quarter of Fiscal 2009
8. GEN reports on novel tools for deciphering biological networks
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
11. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):
(Date:7/14/2017)... , ... July 14, 2017 , ... ... for sample preparation of proteins to clean peptides for mass spectrometry (MS) analysis ... , The PreOmics iST Kit is based on proprietary technology that contains ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... ... URAC accreditation in Specialty Pharmacy. URAC is the independent leader in promoting healthcare ... demonstrated a comprehensive commitment to quality care, improved processes and better patient outcomes. ...
(Date:7/13/2017)... ... July 13, 2017 , ... FireflySci Inc. ... Blast forward seven years and now they are home to a tremendous ... for wavelength accuracy, and resolution testing. , One mega advantage that ...
(Date:7/13/2017)... ... July 13, 2017 , ... After 11 years developing ... Center, Christopher Laing, MRCVS, Ph.D. has been tapped to lead the effort to ... become the first Executive Director at the newly formed Capital City Innovation effective ...
Breaking Biology Technology: